Searchable abstracts of presentations at key conferences in endocrinology

ea0065op1.4 | Adrenal and Cardiovascular | SFEBES2019

Global phosphoproteomics links rapidly induced cytoplasmic signals to transcriptional control

Leslie Fiona , Kershaw Stephen , Pfander Pauline , Poolman Toryn , McGinnis Kathryn , Frankavilla Chiara , Ray David , Cook Graham , Matthews Laura

Glucocorticoids (Gc) are potent anti-inflammatory steroids which mediate their effects by binding the glucocorticoid receptor (GR). Following ligand binding, GR initiates rapid ‘non-genomic’ kinase signals in the cytoplasm, then translocates into the nucleus to mediate ‘genomic’ effects by binding DNA directly or tethering to other DNA bound transcription factors to modulate target gene expression. Little is known about how rapidly induced cytoplasm derived...

ea0041gp33 | Bone & Calcium Homeostasis | ECE2016

Relationships between lower-limb muscle strength and tibial outcomes in ageing UK men

Zengin Ayse , Pye Stephen R , Cook Michael J , Adams Judith E , Wu Frederick C W , O'Neill Terence W , Ward Kate A

Ageing is associated with sarcopenia, osteoporosis and an increased risk of falling, which together contribute to increased fracture risk. There are few data describing the associations between functional measures of muscle and bone during ageing. Therefore, the aim of this study was to examine in ageing men associations between measures of lower-limb muscle strength and age and then to investigate the relationships with tibial bone outcomes.Men (n</...

ea0059p001 | Adrenal and steroids | SFEBES2018

Glucocorticoids promote DNA repair to reduce efficacy of radiotherapy in Glioblastoma

Mc Ginnis Kathryn , Baker Syed Murtuza , Berry Andrew , Ward Thomas , Rattray Magnus , Ray David , Cook Graham , Bond Jacquelyn , Matthews Laura

Glioblastoma (GBM) is a highly aggressive form of brain cancer with a median survival time of 12–15 months from diagnosis. Standard therapies utilise a combination of radiotherapy, chemotherapy, and surgery. Patients also receive high doses of the potent anti-inflammatory glucocorticoid (Gc), Dexamethasone (Dex).Recent studies show that patients receiving the highest dose of Dex also have reduced survival time. Defining pathways under Gc control relevant to GBM is necessa...

ea0058oc4.4 | Oral Communications 4 | BSPED2018

Identification and characterisation of a small-molecule ACTH receptor/Melanocortin-2-receptor antagonist

Chan Li , Hussain Mashal , Forfar Rachel , Khurana Puneet , Cook Jennifer , Lewis Steve , McIver Ed , Jerman Jeff , Taylor Debra , Clark Adrian

The overproduction of ACTH, in conditions such as Congenital Adrenal Hyperplasia (CAH) leads to significant morbidity. Current treatment with glucocorticoids does not adequately suppress plasma ACTH, resulting in excess adrenal androgen production. At present, there is no effective medical treatment that would directly block ACTH action. Such a therapy, especially one that can be orally administered, would be of great clinical value allowing a ‘block and replace’ tre...

ea0028p175 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2012

6q24 Transient Neonatal Diabetes Mellitus (TNDM)-16 years of data collection.

Kabwama S , Docherty L , Cook E , Harrison L , Ellard S , Ennis S , Shield J , Mackay D , Temple I

Introduction: TNDM due to genetic aberrations at 6q24 is the commonest cause of diabetes presenting within the first week of life. TNDM predisposes to diabetes mellitus in later life. We report on the clinical presentation of the largest worldwide cohort of 6q24 TNDM cases.Results: 164 cases were analysed. The mean age of presentation was 8 days with a mode of 1 day and maximum age of presentation of 90 days. On average, babies recovered by 4.5 months wi...

ea0022p619 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Lymphocytic hypophysitis: clinical characteristics and endocrine features of 64 GH deficient patients in KIMS: Pfizer International Metabolic Database

Bensing Sophie , Jonsson Peter , Hulting Anna-Lena , Cook David , Gordon Murray , Faust Michael , Koltowska-Haggstrom Maria , Casanueva Felipe

Objective: To characterize patients with GH deficiency associated with lymphocytic hypophysitis (LyH).Method: Patients with a diagnosis of LyH were identified in the KIMS database. The responsible clinicians were asked to confirm the diagnosis and to provide more detailed information on the patient by filling in a questionnaire.Results: One hundred and fifty patients with a diagnosis of LyH were identified in the database and 100 c...

ea0080p6 | Abstracts | UKINETS2021

Earlier diagnosis of neuroendocrine tumours (NETs) through transformation of the south wales NET service

Gould Harriet , Amin Kapish , Karategos Thanos , Abbas Sarah , Taylor Rebecca , Cook Katherine , Powell Catherine , Hargest Rachel , Phillips Simon , Horwood James , Cornish Julie , Torkington Jared , Khan Mohid

Background: Neuroendocrine tumours (NETs) are heterogeneous cancers with varied survival, arising mainly from the gastroenteropancreatic tract. Delayed diagnosis and mislabelling are widely recognised internationally in midgut NETs with little data describing how to improve diagnosis times. In 2017, transformation of the South Wales NET Service included a change to a gastroenterology-led service model alongside education and forming working relationships with gastroenterologis...

ea0086oc3.3 | Reproductive and Neuroendocrinology | SFEBES2022

Long-term efficacy and safety of oral, once-daily paltusotine treatment in acromegaly: Two-year interim results from the ACROBAT Advance study

Randeva Harpal , Gadelha Monica , Gordon Murray , Doknic Mirjana , Mezősi Emese , Toth Miklos , Boguszewski Cesar , Ferrara-Cook Christine , Casagrande Alessandra , Krasner Alan

Paltusotine is an investigational oral, once-daily, non-peptide, SST2 agonist in development for the treatment of acromegaly and neuroendocrine tumors. Interim analysis results from subjects with acromegaly treated with paltusotine for up to 2 years in ACROBAT Advance (NCT04261712), an ongoing, open-label extension study are reported here. Prior to Advance, subjects previously completed one of two Phase 2 parent studies, Evolve (NCT03792555, with normal IGF-1 using injected lo...

ea0086p344 | Neuroendocrinology and Pituitary | SFEBES2022

CRN04894: an oral, nonpeptide adrenocorticotropic hormone (ACTH) receptor antagonist decreases basal and stimulated cortisol secretion in healthy volunteers

Trainer Peter , Ferrara-Cook Christine , Ayala Alejandro , Luo Rosa , Miller Stephanie , Wang Yang , Hernandez-Illas Martha , Scott Struthers R. , Betz Stephen , Krasner Alan

CRN04894 is a potent, orally bioavailable nonpeptide that is a highly selective antagonist for melanocortin type 2 receptor (MC2R). This receptor is found exclusively in the adrenal cortex and is the primary mediator of adrenal activation. We report results from a randomized, double-blinded, placebo-controlled (6 active:3 placebo/cohort), multiple ascending dose (40, 60, and 80 mg) study in health volunteers evaluating safety, pharmacokinetics, and pharmacodynamics of oral, on...

ea0087p2 | Poster Presentations | UKINETS2022

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Khan Mohid , Davies Louise , Back Melissa , Shah Tahir , Pritchard Mark , Cook Kathryn , Hull Diana , McKane Gail , Day Melissa , Grandoulier Anne-Sophie , Higgs Kate

Introduction: LAN, a somatostatin analogue, is a common first-line treatment for NETs. LAN comes as a pre-filled, ready-to-use syringe, administered every 4 weeks. In the UK, patients may receive LAN at home. The aim of PREF-NET was to generate real-world evidence describing patient’s experience of LAN administered in homecare and hospital settings, and the associated impact of treatment setting on other areas of patients’ lives.Methods: PREF-N...